A Capsida scientist at work in the company’s laboratory in Thousand Oaks. (courtesy photo) Thousand Oaks-based Capsida ...

AbbVie Inc. will record a $3.5 billion charge after a schizophrenia drug it gained in the purchase of Cerevel Therapeutics Inc. failed in clinical trials. The experimental drug, emraclidine, failed to ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the emraclidine intangible asset acquired as part of the ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger from Leerink Partners maintained a Buy rating on the ...

AbbVie will clearly fight to keep its top-selling Humira (adalimumab) anti-inflammatory drug on the market for as long as possible – but it also has one eye on a possible successor that is ...

AbbVie ABBV underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by ...

THOUSAND OAKS, Calif., Jan. 7, 2025 /PRNewswire/ -- Capsida Biotherapeutics (“Capsida”) today announced that AbbVie has exercised an option for the first neurodegenerative disease program under their ...

Capsida Biotherapeutics yesterday revealed US pharma major AbbVie (NYSE: ABBV) has exercised an option for the first neurodegenerative disease program under their ongoing collaboration. As a result, ...